SEC Filing Summary: Signal Genetics, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Signal Genetics, Inc. on November 30, 2015, regarding an event dated November 24, 2015. The filing addresses a regulatory notice received from the NASDAQ Stock Market concerning the Company's compliance with continued listing standards. Note: The request metadata referenced "Viridian Therapeutics, Inc.", but the source document explicitly identifies the registrant as Signal Genetics, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the market price of the Company's common stock, which closed below the minimum $1.00 per share requirement for the last 30 consecutive business days.
Material Changes
The material change reported is the receipt of a deficiency letter from the NASDAQ Listing Qualifications Department. This notice confirms that the Company failed to maintain the minimum $1.00 bid price required under NASDAQ Listing Rule 5550(a)(2) for the preceding 30 business days.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has been granted 180 calendar days, until May 23, 2016, to regain compliance.
- Compliance Criteria: To regain compliance, the bid price must close at $1.00 or more for a minimum of 10 consecutive business days before May 23, 2016.
- Alternative Path: If the Company fails to meet the bid price requirement but meets other initial inclusion criteria (Listing Rule 5505), it may be granted an additional 180-day compliance period.
- Delisting Risk: If compliance is not achieved by May 23, 2016, and no additional period is granted, the Company's stock may be delisted.
- Appeal Process: The Company may appeal a delisting determination to a NASDAQ Listing Qualifications Panel, though there is no assurance of success. The stock would remain listed pending the Panel's decision.
Investor Verification Checklist
- Verify the current trading price of Signal Genetics, Inc. common stock to assess progress toward the $1.00 threshold.
- Monitor the Company's stock performance over the next 10 consecutive business days to determine if the immediate compliance window is met.
- Review future filings for updates on the May 23, 2016 deadline or any announcements regarding an appeal to the NASDAQ Listing Qualifications Panel.
- Confirm whether the Company has initiated a reverse stock split or other corporate actions to address the low bid price.